Early detection of response to experimental chemotherapeutic top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice

PLoS ONE

Volumn 5, Issue 9, 2010, Pages

  Jensen, Mette Munk ^a,b   Erichsen, Kamille Dumong ^c   Björkling, Fredrik ^c   Madsen, Jacob ^b   Jensen, Peter Buhl ^c   Højgaard, Liselotte ^a,b   Sehested, Maxwell ^c   Kjær, Andreas ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c BioAlliance Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; THYMIDINE KINASE 1; TOP 216; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE TRACING; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG MONITORING; DRUG SCREENING; EVALUATION; INSTRUMENTATION; METHODOLOGY; NUDE MOUSE; OVARY TUMOR; PATHOPHYSIOLOGY; SCINTISCANNING;

ANIMALIA; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; DRUG MONITORING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958576120     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012965     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
2. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336.
3. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, et al. (1992) Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 39-fluoro-39-deoxythymidine and 39-azido-39-deoxythymidine. Antimicrob Agents Chemother 36: 808-818.
4. Arner ES, Eriksson S (1995) Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67: 155-186.
5. Sherley JL, Kelly TJ (1988) Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358.
6. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43: 1210-1217.
7. Barthel H, Perumal M, Latigo J, He Q, Brady F, et al. (2005) The uptake of 39- deoxy-39-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32: 257-263.
8. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, et al. (2003) 39-deoxy-39-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798.
9. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, et al. (2005) Early detection of tumor response to chemotherapy by 39-deoxy-39-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65: 4202-4210.
10. Leyton J, Alao JP, Da CM, Stavropoulou AV, Latigo JR, et al. (2006) In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 39-deoxy-39-[18F]fluorothymidine positron emission tomography. Cancer Res 66: 7621-7629.
11. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, et al. (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 39-deoxy-39-18F-fluorothymidine PET. J Nucl Med 46: 114-120.
12. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, et al. (2003) Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 44: 1426-1431.
13. Francis DL, Freeman A, Visvikis D, Costa DC, Luthra SK, et al. (2003) In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 52: 1602-1606.
14. Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, et al. (2002) In vivo validation of 39deoxy-39-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8: 3315-3323.
15. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, et al. (2006) Early detection of chemoradioresponse in esophageal carcinoma by 39-deoxy-39- 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12: 4590-4597.
16. Brepoels L, Stroobants S, Verhoef G, De GT, Mortelmans L, et al. (2009) 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model. J Nucl Med 50: 1102-1109.
17. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van GM, et al. (2007) Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 29-deoxy-29-[18F]fluoro-D-glucose (FDG) and 39- [18F]fluoro-39-deoxythymidine (FLT). Mol Imaging Biol 9: 340-347.
18. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, et al. (2004) Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45: 519-525.
19. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, et al. (2006) Use of 39-deoxy-39- [18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33: 412-419.
20. Manning HC, Merchant NB, Foutch AC, Virostko JM, Wyatt SK, et al. (2008) Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 14: 7413-7422.
21. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, et al. (2009) Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15: 4712-4721.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
24. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1): 122S-150S.
25. Weber WA, Wieder H (2006) Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 33(Suppl 1): 27-37.
26. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, et al. (1992) Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33: 1972-1980.
27. van WA, Cobben DC, Suurmeijer AJ, Maas B, Waalburg W, et al. (2004) Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45: 695-700.
28. Uddin MK, Reignier SG, Coulter T, Montalbetti C, Granas C, et al. (2007) Syntheses and antiproliferative evaluation of oxyphenisatin derivatives. Bioorg Med Chem Lett 17: 2854-2857.
29. Jensen MM, Jorgensen JT, Binderup T, Kjaer A (2008) Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 8: 16.
30. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, et al. (2006) Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med 47: 999-1006.
31. Fleige S, Pfaffl MW (2006) RNA integrity and the effect on the real-time qRTPCR performance. Mol Aspects Med 27: 126-139.
32. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
33. Pfaffl MW (2001) A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 29: e45.
34. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, et al. (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102: 75-84.
35. Chang ZF, Huang DY, Hsue NC (1994) Differential phosphorylation of human thymidine kinase in proliferating and M phase-arrested human cells. J Biol Chem 269: 21249-21254.
36. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G (1995) Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69-89.